Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)
CNY 13.74
(3.85%)
CNY 13.74
(3.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 11.58 Million CNY | -96.58% |
| 2022 | 338.85 Million CNY | 137.75% |
| 2021 | 142.52 Million CNY | -8.62% |
| 2020 | 155.96 Million CNY | 3.35% |
| 2019 | 150.9 Million CNY | 56.62% |
| 2018 | 96.34 Million CNY | 115.66% |
| 2017 | 44.67 Million CNY | -43.33% |
| 2016 | 78.84 Million CNY | 2.37% |
| 2015 | 77.02 Million CNY | 5.9% |
| 2014 | 72.73 Million CNY | 5.4% |
| 2013 | 69 Million CNY | 13.85% |
| 2012 | 60.6 Million CNY | -12.58% |
| 2011 | 69.33 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 44.3 Million CNY | 804.39% |
| 2024 Q1 | 14.04 Million CNY | 132.69% |
| 2024 Q2 | 4.89 Million CNY | -65.11% |
| 2023 Q1 | 43.44 Million CNY | -65.17% |
| 2023 Q4 | -42.95 Million CNY | -281.36% |
| 2023 Q3 | 23.68 Million CNY | 288.05% |
| 2023 Q2 | -12.59 Million CNY | -128.99% |
| 2023 FY | 11.58 Million CNY | -96.58% |
| 2022 Q4 | 124.74 Million CNY | 325.14% |
| 2022 Q3 | 29.34 Million CNY | -57.72% |
| 2022 Q1 | 115.26 Million CNY | 1515.47% |
| 2022 Q2 | 69.39 Million CNY | -39.8% |
| 2022 FY | 338.85 Million CNY | 137.75% |
| 2021 Q4 | 7.13 Million CNY | -62.53% |
| 2021 Q2 | 66 Million CNY | 31.11% |
| 2021 Q1 | 50.34 Million CNY | 91.1% |
| 2021 FY | 142.52 Million CNY | -8.62% |
| 2021 Q3 | 19.04 Million CNY | -71.15% |
| 2020 Q1 | 43.61 Million CNY | 90.14% |
| 2020 Q4 | 26.34 Million CNY | -21.44% |
| 2020 Q3 | 33.53 Million CNY | -47.51% |
| 2020 Q2 | 63.87 Million CNY | 46.45% |
| 2020 FY | 155.96 Million CNY | 3.35% |
| 2019 FY | 150.9 Million CNY | 56.62% |
| 2019 Q1 | 42.24 Million CNY | 32.2% |
| 2019 Q2 | 44.05 Million CNY | 4.28% |
| 2019 Q3 | 41.67 Million CNY | -5.4% |
| 2019 Q4 | 22.93 Million CNY | -44.95% |
| 2018 FY | 96.34 Million CNY | 115.66% |
| 2018 Q4 | 31.95 Million CNY | 65.12% |
| 2018 Q3 | 19.35 Million CNY | -47.95% |
| 2018 Q2 | 37.17 Million CNY | 372.59% |
| 2018 Q1 | 7.86 Million CNY | -13.37% |
| 2017 FY | 44.67 Million CNY | -43.33% |
| 2017 Q1 | 13.28 Million CNY | -23.01% |
| 2017 Q4 | 9.08 Million CNY | 228.24% |
| 2017 Q3 | 2.76 Million CNY | -85.85% |
| 2017 Q2 | 19.54 Million CNY | 47.17% |
| 2016 Q1 | 12.19 Million CNY | 0.0% |
| 2016 Q4 | 17.25 Million CNY | -17.89% |
| 2016 Q3 | 21 Million CNY | -26.01% |
| 2016 FY | 78.84 Million CNY | 2.37% |
| 2016 Q2 | 28.39 Million CNY | 132.92% |
| 2015 FY | 77.02 Million CNY | 5.9% |
| 2014 Q2 | 17.22 Million CNY | 0.0% |
| 2014 Q1 | 17.22 Million CNY | 0.0% |
| 2014 FY | 72.73 Million CNY | 5.4% |
| 2013 FY | 69 Million CNY | 13.85% |
| 2012 FY | 60.6 Million CNY | -12.58% |
| 2011 FY | 69.33 Million CNY | 0.0% |